CKD 516

Drug Profile

CKD 516

Alternative Names: CKD-516; NOV 1204; NOV-120401

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chong Kun Dang
  • Class
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Colorectal cancer
  • Phase I Solid tumours

Most Recent Events

  • 07 Nov 2017 CKD 516 is still in phase I trials for Solid tumours in USA (IV, Injection) (National OncoVenture pipeline, November 2017)
  • 01 Dec 2016 Phase-I/II clinical trials in Colorectal cancer (Combination therapy, Second-line therapy or greater, Late-stage disease) in South Korea (PO) (NCT03076957)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in South Korea (IV, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top